Petz Aladar Megyei Oktato Korhaz psychedelic research trials
Data as of 31 October 2026. Source: ClinicalTrials.gov records held by PsychoactiveMap, refreshed from a reviewed snapshot.
Petz Aladar Megyei Oktato Korhaz is listed with 4 registered studies counted here, in Győr, Hungary. By compound: 4 ketamine. By registry status: 1 recruiting and 3 completed. By phase: 3 phase 3 and 1 phase 4. Reported start years run from 2017 (earliest) to 2026 (latest).
Institution name, city and country are copied from the research site linked to each registry record. A study counts once per institution, and a study tagged with more than one compound is counted under each compound.
Educational information, not medical advice. A registry listing is not evidence of safety, benefit or results, and it is not a recommendation. PsychoactiveMap does not recruit, screen or refer participants. Status and other details are copied from the registry and can be out of date, so check the registry record and speak to a qualified health professional before any decision. Read the full disclaimer.
At a glance
- 4 registered studies are counted on this page.
By compound
| Compound hub | Studies |
|---|---|
| Ketamine | 4 |
By registry status
| Status | Studies | Share |
|---|---|---|
| Recruiting | 1 | 25% |
| Completed | 3 | 75% |
By phase
| Phase | Studies | Share |
|---|---|---|
| Phase 3 | 3 | 75% |
| Phase 4 | 1 | 25% |
Registered studies
All counted studies, newest start first. Dates may be estimated, including future dates; a listed date does not confirm that a study started. The order is not a ranking and says nothing about quality. Titles are quoted from the registry. Each ID links to its own ClinicalTrials.gov record, which has the eligibility criteria and contacts.
| Title as registered | Registry ID | Status | Phase | Registry dates | Compound |
|---|---|---|---|---|---|
| A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder | NCT07227454 | Recruiting | Phase 3 | Source start: 2026-01-08 (actual)Source date detailsStart: 2026-01-08 (precision: day; source type: ACTUAL; actual) Primary completion: 2031-04-09 (precision: day; source type: ESTIMATED; estimated) Study completion: 2031-09-15 (precision: day; source type: ESTIMATED; estimated) Observation retrieved: 2026-10-31T20:06:18.160Z; registry revision: 2026-09-25 (precision: day; source type: ACTUAL; actual). Source observations do not verify a different saved scalar or establish that an event occurred. | Ketamine |
| A Long-Term Extension Study for Participants With Treatment-resistant Major Depressive Disorder Who Are Continuing Esketamine Nasal Spray Treatment | NCT04829318 | Completed | Phase 4 | Source start: 2021-04-26 (actual)Source date detailsStart: 2021-04-26 (precision: day; source type: ACTUAL; actual) Primary completion: 2024-07-22 (precision: day; source type: ACTUAL; actual) Study completion: 2024-07-22 (precision: day; source type: ACTUAL; actual) Observation retrieved: 2026-10-31T20:06:15.827Z; registry revision: 2025-09-18 (precision: day; source type: ACTUAL; actual). Source observations do not verify a different saved scalar or establish that an event occurred. | Ketamine |
| A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in Participants With Treatment Resistant Major Depressive Disorder | NCT04338321 | Completed | Phase 3 | Source start: 2020-08-21 (actual)Source date detailsStart: 2020-08-21 (precision: day; source type: ACTUAL; actual) Primary completion: 2022-01-20 (precision: day; source type: ACTUAL; actual) Study completion: 2022-07-15 (precision: day; source type: ACTUAL; actual) Observation retrieved: 2026-10-31T20:06:12.343Z; registry revision: 2025-04-29 (precision: day; source type: ACTUAL; actual). Source observations do not verify a different saved scalar or establish that an event occurred. | Ketamine |
| 54135419SUI3001: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Adult Participants Assessed to be at Imminent Risk for Suicide | NCT03039192 | Completed | Phase 3 | Source start: 2017-06-09 (actual)Source date detailsStart: 2017-06-09 (precision: day; source type: ACTUAL; actual) Primary completion: 2018-12-18 (precision: day; source type: ACTUAL; actual) Study completion: 2018-12-18 (precision: day; source type: ACTUAL; actual) Observation retrieved: 2026-10-31T20:06:14.289Z; registry revision: 2025-04-29 (precision: day; source type: ACTUAL; actual). Source observations do not verify a different saved scalar or establish that an event occurred. | Ketamine |
About this data
Compound tags come from automated matching of the registry search term and have not been checked record by record. Counts are of registered studies, not of people, results or approvals. A registry listing is not evidence of safety, benefit or results.
Substance hubs for these compounds
Country hub: Hungary